Article
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2017
Jovanović Bojana, Mayer Ingrid A, Mayer Erica L, Abramson Vandana G, Bardia Aditya, Sanders Melinda E, Kuba M Gabriela, Estrada Monica V, Beeler J Scott, Shaver Timothy M, Johnson Kimberly C, Sanchez Violeta, Rosenbluth Jennifer M, Dillon Patrick M, Forero-Torres Andres, Chang Jenny C, Meszoely Ingrid M, Grau Ana M, Lehmann Brian D, Shyr Yu, Sheng Quanhu, Chen Sheau-Chiann, Arteaga Carlos L, Pietenpol Jennifer A
Abstract excerpt
Purpose: Because of inherent disease heterogeneity, targeted therapies have eluded triple-negative breast cancer (TNBC), and biomarkers predictive of treatment response have not yet been identified. This study was designed to determine whether the mTOR inhibitor everolimus with cisplatin and paclitaxel would provide synergistic antitumor effects in TNBC.Methods: Patients with stage II/III TNBC were enrolled in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.